Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2013 > Volume 22 Number 5 September 2013 > INFECTIVE ENDOCARDITIS > Postoperative Warfarin Following Mitral Valve Repair or Bioprosthetic Valve Replacement

Postoperative Warfarin Following Mitral Valve Repair or Bioprosthetic Valve Replacement

Vinod H. Thourani1, Rebecca L. Gunter1, Stuart Hurst1, Patrick Kilgo2, Murali Padala1, John D. Puskas1, Omar M. Lattouf1, Michael E. Halkos1, Robert A. Guyton1

1Structural Heart and Valve Program, Clinical Research Unit, Division of Cardiothoracic Surgery, and 2Department of Biostatistics, Rollins School of Public Health, Emory University School of Medicine, Atlanta, Georgia, USA

Background and aim of the study: Short-term postoperative warfarin therapy has been used to decrease neurologic events following mitral valve repair or bioprosthetic replacement (MVR). The study aim was to compare the short- and long-term outcomes of patients undergoing mitral valve surgery with or without short-term postoperative warfarin.

Methods: A single academic US institution retrospective review was performed on discharged patients who underwent MVR between January 1996 and March 2010. Patients were allocated to two groups: MVR with four to six weeks of postoperative warfarin (n = 315; Warfarin group) or MVR without postoperative warfarin (n = 257; No warfarin group). Patients who required either preoperative or postoperative warfarin for any disease process (e.g., atrial fibrillation, mechanical valve, deep venous thrombosis) were excluded. Logistic and Cox proportional hazards regression models were constructed to evaluate the effects of warfarin on short- and long-term outcomes, respectively. Adjusted odds ratios (AOR) and adjusted hazard ratios (AHR), with 95% confidence intervals (CI) were constructed for each outcome. To reduce selection


bias, propensity scoring methods were employed to balance the groups with respect to 54 preoperative variables.

Results: Mean age was not significantly different between groups (No warfarin group = 56.8 ± 14.5 years versus Warfarin group 55.9 ± 12.9 years; p = 0.46). The average length of hospital stay was 9.8 ± 8.4 days and 7.3 ± 4.5 days in the No warfarin and Warfarin groups, respectively (p <0.001). At the six-week follow up the incidences of stroke (p = 0.74), pleural effusions (p = 0.88), pericardial effusions (p = 0.75), and bleeding complications (p=0.30) were similar between the two groups. In an unadjusted Kaplan-Meier analysis, the No warfarin group had a poorer long-term survival than the Warfarin group (p <0.001). However, after propensity adjustment, the benefit of warfarin was not statistically significant (AHR = 0.66, 95% CI 0.40-1.08, p = 0.098).

Conclusion: The use of postoperative warfarin following MVR does not reduce the incidence of stroke at early follow up. However, there remains a trend for improved long-term outcomes in those patients receiving postoperative warfarin therapy.

The Journal of Heart Valve Disease 2013;22:716-723

Postoperative Warfarin Following Mitral Valve Repair or Bioprosthetic Valve Replacement

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.